Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | TNKS | O95271 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 3/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | PLG | P00747 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | PLAT | P00750 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11247199 | 0.89 | FFAR1 (0.57) | FFAR1MAOBHDAC6TNKSIDO1 | |
| SCHEMBL3922682 | 0.87 | ESR1 (0.68) | FFAR1MAOBTNKSESR1ESR2 | |
| SCHEMBL30285970 | 0.87 | CSNK2A1 (0.52) | FFAR1MAOBHDAC6TNKSTTR | |
| SCHEMBL977056 | 0.87 | HDAC6 (0.73) | FFAR1MAOBHDAC6TNKSTTR | |
| SCHEMBL3121270 | 0.86 | NPC1 (0.52) | FFAR1TNKSIDO1ESR1ESR2 | |
| SCHEMBL5209380 | 0.86 | MAOB (0.58) | FFAR1MAOBHDAC6TNKSESR1 | |
| SCHEMBL11243729 | 0.86 | FFAR1 (0.55) | FFAR1MAOBHDAC6TNKSIDO1 | |
| SCHEMBL11243734 | 0.86 | FFAR1 (0.55) | FFAR1MAOBHDAC6TNKSIDO1 | |
| SCHEMBL19029211 | 0.84 | HDAC6 (0.79) | FFAR1MAOBHDAC6IDO1 | |
| SCHEMBL979562 | 0.84 | PIM1 (0.59) | FFAR1MAOBHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107383024-B | The class compound of fused tricyclic containing imidazoles and its application | 广州必贝特医药技术有限公司 | 2018-06-08 | — | — | CN | disclosed |
| CN-107383024-A | The class compound of fused tricyclic containing imidazoles and its application | 广州必贝特医药技术有限公司 | 2017-11-24 | — | — | CN | disclosed |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | disclosed |
| EP-2217566-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | disclosed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | disclosed |
| WO-2009064250-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064251-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| EP-0858454-B1 | COMBINATORIAL SOLID PHASE SYNTHESIS OF A LIBRARY OF BENZOFURAN DERIVATIVES | PHARMACIA & UPJOHN SPA (IT) | 2001-06-20 | — | — | EP | disclosed |
| US-5919955-A | IMMOBILIZATION ON SUPPORT; DEPROTECTING; REACTING WITH ACETYLENIC COMPOUND; CLEAVAGE FROM SUPPORT | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-07-06 | — | — | US | disclosed |
| EP-0858454-A1 | COMBINATORIAL SOLID PHASE SYNTHESIS OF A LIBRARY OF BENZOFURAN DERIVATIVES | PHARMACIA & UPJOHN S.p.A. (IT) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997044338-A1 | COMBINATORIAL SOLID PHASE SYNTHESIS OF A LIBRARY OF BENZOFURAN DERIVATIVES | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | PTGER1, CYP3A5, SULT1E1 | FFAR1 121/4885MAOB 406/4885HDAC6 3409/4885 |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | FFAR1 113/4885MAOB 337/4885HDAC6 3831/4885 |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | FFAR1 113/4885MAOB 337/4885HDAC6 3831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.